First-in-class, protein-protein interaction inhibitors against invasive cancers.
Location: Switzerland, Zurich
Employees: 1-10
Total raised: $4.61M
Investors 5
| Date | Name | Website |
| 16.06.2022 | OCCIDENT | occident.g... |
| - | Verve Vent... | verve.vc |
| - | Venture Ki... | venturekic... |
| - | VentureLab | venturelab... |
| 08.06.2022 | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.06.2022 | Seed | $4.61M | - |
Mentions in press and media 3
| Date | Title | Description |
| 19.04.2023 | Ten biotech startups head to Boston | |
| 07.06.2022 | Invasight closes CHF 4.5 million oversubscribed seed round | June 7, 2022 |
| 07.06.2022 | Invasight closes CHF 4.5 million seed round to fight invasive cancers |